Healthcare Providers and Services
Company Overview of Pathway Genomics Corporation
Pathway Genomics Corporation designs genetic tests in the United States and internationally. The company offers physicians with genetic testing reports on diet and exercise, drug response, carrier status, and complex health conditions. It offers testing services for specific conditions and traits, such as aerobic capacity (VO2max), asthma, beta thalassaemia, cystic fibrosis, Type 1 and Type 2 diabetes, eating behaviors, exercise response, food reactions, hypertension, matching diet type, metabolic health factors, Omega-6 and Omega-3 levels, rheumatoid arthritis, statin and warfarin response, vitamin C, and others. The company also offers DNA reports that offer insight related to cardiac heal...
4045 Sorrento Valley Boulevard
San Diego, CA 92121
Founded in 2008
Key Executives for Pathway Genomics Corporation
President of Pathway Genomics International
Chief Technology Officer and Vice President of Engineering & Product Development
Compensation as of Fiscal Year 2014.
Pathway Genomics Corporation Key Developments
Myriad Genetics and Pathway Genomics Agree to Settle BRCA Patent Infringement Case
Jan 23 15
Pathway Genomics Corporation announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014. Under the agreement, Myriad Genetics Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche Inc., and the Trustees of the University of Pennsylvania and Pathway dismiss their respective claims and counterclaims against one another in the BRCA patent litigation. Additionally, the Patent Owners granted a covenant to not sue Pathway under the patents asserted in the litigation proceedings. The decision to settle follows an opinion from the United States Court of Appeals for the Federal Circuit on Dec. 17, 2014 that ruled some of the key patent claims at issue in the case were directed to ineligible subject matter under 35 U.S.C. §101.
Pathway Genomics Corporation Names Glenn D. Braunstein to its Medical Advisory Board
Nov 6 14
Pathway Genomics Corporation announced that world-renowned endocrinologist Dr. Glenn D. Braunstein has joined Pathway Genomics' medical advisory board. Dr. Braunstein is currently the vice president of clinical innovation, director of the Thyroid Cancer Center and professor of medicine at Cedars-Sinai. For 26 years he served as chair of the Department of Medicine at Cedars-Sinai, and holds the James R. Klinenberg, M.D., Chair in Medicine. Dr. Braunstein is a member of a number of academic organizations, including the Endocrine Society, the American Thyroid Association, the American Society for Clinical Investigation and the Association of American Physicians. He is a past chair of the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration (FDA) and currently serves as special advisor. Dr. Braunstein also served as chair of the Endocrinology, Diabetes and Metabolism Subspecialty Boards for the American Board of Internal Medicine.
Pathway Genomics Corporation Appoints Jennifer Skeen as Vice President of Clinical Operations
Sep 25 14
Pathway Genomics Corporation announced that it has appointed Jennifer Skeen as its vice president of clinical operations. Based at Pathway Genomics San Diego headquarters, Dr. Skeen brings to the company more than 20 years of experience in the molecular diagnostics and biotech industries in both U.S. and international markets. Skeen's experience is broad, having served roles in research and development, commercialization, clinical laboratory operations, and executive management in both public and private sectors. Most recently, Dr. Skeen was the laboratory director at Asuragen, where she was responsible for the overall operation and administration of a 70,000 square-foot laboratory.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 12, 2014
April 1, 2014